Form 4 for EDIT Editas Medicine, Inc.
Accepted 2022-06-06 00:00:00 ET · period of report 2022-06-02 · accession 0001415889-22-006159 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-06 | 2022-06-02 | EDIT | O'Neill Gilmore Neil | CEO, Dir | A - Grant | $0.00 | +86.7K | 86.7K | New | $0 |
| D | 2022-06-06 | 2022-06-02 | EDIT | O'Neill Gilmore Neil | CEO, Dir | A - Grant | $0.00 | +950.2K | 950.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-02 | A | A | 86,655 | $0.00 | 86,655 | D | — | — | (F1) The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 2, 2023 continuing through June 2, 2026. |
| 2 | Derivative | Stock Option (right to buy) | 2022-06-02 | A | A | 950,209 | $0.00 | 950,209 | D | $11.54 · — to 2032-06-01 | 950,209 Common Stock | (F2) This option was granted on June 2, 2022 and is scheduled to vest over four years, with 25% of the shares scheduled to vest on June 2, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 2, 2026. |